Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Core Insights - Apellis Pharmaceuticals will host a conference call on October 30, 2025, to discuss its third quarter 2025 financial results [1] - The call will be accessible via phone and a live audio webcast, with a replay available for 90 days [2] Company Overview - Apellis Pharmaceuticals is a global biopharmaceutical company focused on complement science, developing therapies for challenging diseases [3] - The company has introduced the first new class of complement medicine in 15 years, with two C3-targeting medicines approved for four serious diseases [3] - Notable breakthroughs include the first therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients aged 12 and older with C3G or primary IC-MPGN, both severe kidney diseases [3] - Apellis believes there is significant potential in targeting C3 across various serious diseases [3]